Trial Profile
A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Clinical Efficacy and Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Peptide p277 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DIA-AID-2
- Sponsors Andromeda Biotech
- 19 Apr 2016 Status changed from active, no longer recruiting to completed.
- 29 Nov 2014 Planned number of patients changed from 450 to 474, according to European Clinical Trials Database record.
- 08 Sep 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014, according to a Hyperion Therapeutics media release.